La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Pharvaris Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Berndt Axel Modig

Amministratore delegato

€532.0k

Compenso totale

Percentuale dello stipendio del CEO	100.0%
Mandato del CEO	9yrs
Proprietà del CEO	2.8%
Durata media del management	2.6yrs
Durata media del Consiglio di amministrazione	3.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Berndt Axel Modig rispetto agli utili di Pharvaris?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-€114m
Mar 31 2024	n/a	n/a	-€106m
Dec 31 2023	€532k	€532k	-€101m
Sep 30 2023	n/a	n/a	-€107m
Jun 30 2023	n/a	n/a	-€92m
Mar 31 2023	n/a	n/a	-€83m
Dec 31 2022	€500k	€500k	-€76m
Sep 30 2022	n/a	n/a	-€49m
Jun 30 2022	n/a	n/a	-€50m
Mar 31 2022	n/a	n/a	-€53m
Dec 31 2021	€414k	€414k	-€43m
Sep 30 2021	n/a	n/a	-€41m
Jun 30 2021	n/a	n/a	-€38m
Mar 31 2021	n/a	n/a	-€29m
Dec 31 2020	€404k	€404k	-€26m

Compensazione vs Mercato: La retribuzione totale di Berndt Axel ($USD 591.90K ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 3.30M ).

Compensazione vs guadagni: La retribuzione di Berndt Axel è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Berndt Axel Modig (65 yo)

9yrs

Mandato

€532,000

Compensazione

Mr. Berndt Axel Edvard Modig, MBA, CPA, serves as Chief Executive Officer since 2015 and Executive Director of Pharvaris B.V. Mr. Modig served as a Member of the Supervisory Board at Centogene N.V. since A...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Berndt Axel Modig	Co-Founder	9yrs	€532.00k	2.79% € 28.2m
Anna Nijdam	Head of Strategic Finance & Principal Accounting Officer	no data	Nessun dato	0.093% € 942.6k
Stefan Abele	Chief Technology Operations Officer	less than a year	Nessun dato	Nessun dato
Annick Deschoolmeester	Chief Human Resources Officer	2yrs	Nessun dato	0.033% € 334.9k
Peng Lu	Chief Medical Officer	4.6yrs	Nessun dato	0.84% € 8.5m
Anne Lesage	Chief Early Development Officer	no data	Nessun dato	0.93% € 9.4m
Morgan Conn	Chief Business Officer	no data	Nessun dato	0.50% € 5.1m
Wim Souverijns	Chief Commercial Officer	3.2yrs	Nessun dato	0.20% € 2.0m
David Nassif	CFO & Corporate Secretary	less than a year	Nessun dato	Nessun dato
Maryann Cimino	Director of Corporate Relations	no data	Nessun dato	Nessun dato

2.6yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di PHVS è considerato esperto (durata media dell'incarico 2.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Berndt Axel Modig	Co-Founder	no data	€532.00k	2.79% € 28.2m
Robert Glassman	Independent Non-Executive Director	3.7yrs	€50.50k	0.062% € 626.0k
David Meeker	Independent Non-Executive Chair	3.7yrs	€94.00k	0.23% € 2.3m
Hans J. G. C. Schikan	Independent Vice Chairman	5.1yrs	€61.00k	0.94% € 9.5m
Elisabeth Bjork	Non-Executive Director	2.8yrs	€45.00k	0.041% € 414.7k
Viviane Monges	Non-Executive Director	3.2yrs	€62.50k	0.059% € 595.4k

3.7yrs

Durata media

64yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PHVS sono considerati esperti (durata media dell'incarico 3.6 anni).

Pharvaris Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Pharvaris N.V. Announces Resignation of Morgan Conn as Chief Business Officer, Effective October 4, 2024

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Pharvaris N.V. Appoints David Nassif as Permanent Chief Legal Officer

Pharvaris N.V., Annual General Meeting, Jun 28, 2024

Pharvaris N.V., Annual General Meeting, Jun 28, 2024

Recent updates

Pharvaris N.V. Announces Resignation of Morgan Conn as Chief Business Officer, Effective October 4, 2024

Co-Founder notifies of intention to sell stock

Pharvaris Expands Development Program for Deucrictibant

Co-Founder notifies of intention to sell stock

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Pharvaris N.V. Appoints David Nassif as Permanent Chief Legal Officer

Pharvaris N.V., Annual General Meeting, Jun 28, 2024

Pharvaris N.V., Annual General Meeting, Jun 28, 2024

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

Pharvaris N.V. Announces Chief Legal Officer Changes, Effective June 1, 2024

Chief Business Officer notifies of intention to sell stock

New minor risk - Share price stability

Chief Early Development Officer notifies of intention to sell stock

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

Independent Vice Chairman notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Pharvaris: Digging Deep For Sufficient Market Size

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V. Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-Demand Treatment of HAE At the GA²LEN UCARE Conference 2023

New major risk - Shareholder dilution

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V. has completed a Follow-on Equity Offering in the amount of $299.98625 million.

Pharvaris N.V. has completed a Follow-on Equity Offering in the amount of $299.98625 million.

Pharvaris Announces Positive Top-Line Phase 2 Data from the Chapter-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Co-Founder notifies of intention to sell stock

Pharvaris Appoints Stefan Abele as Chief Technical Operations Officer

New major risk - Revenue and earnings growth

Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Chief Medical Officer notifies of intention to sell stock

New major risk - Share price stability

Co-Founder notifies of intention to sell stock

Pharvaris N.V. Announces Board Changes

Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE

Pharvaris Announces Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023

Pharvaris N.V., Annual General Meeting, Jun 23, 2023

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

Companies Like Pharvaris (NASDAQ:PHVS) Are In A Position To Invest In Growth

Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks

Less than half of directors are independent

Pharvaris Presents Data Supporting HAE Drug Development Strategy At the 2022 HAEi Global Leadership Workshop

Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Pharvaris GAAP EPS of -€0.38

Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S

Pharvaris slips 19% after FDA clinical hold on hereditary angioedema candidate

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V., Annual General Meeting, Jun 29, 2022

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Pharvaris N.V. Appoints Joan Schmidt as Chief Legal Officer

Less than half of directors are independent

High number of new and inexperienced directors

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Pharvaris reports Q1 results

Independent Non-Executive Director has left the company

Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE

Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE

Pharvaris B.V. has completed an IPO in the amount of $165.41 million.

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione